PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in PAD treatment

1174


Michael Jaff (Newton, USA) outlines the major recent developments in best medical therapy that will impact the treatment of peripheral arterial disease (PAD) at VEITHsymposium 2018.

(Visited 364 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here